Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review

E-ISSN： 1873-5592|19|15|1774-1781

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.15, 2018-12, pp. : 1774-1781

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

By McLaughlin John Houghton Lesley A

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 313-327

Informa Healthcare

Access to resources Recommend Favorite

Irritable Bowel Syndrome: New Agents Targeting Serotonin Receptor Subtypes

By De Ponti F.

Drugs, Vol. 61, Iss. 3, 2001-01 ,pp. : 317-332

Adis International

Access to resources Recommend Favorite

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal Berrada Driss Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Safety Profile of Tegaserod, a 5-HT 4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome

By Hasler W.L. Schoenfeld P.

Drug Safety, Vol. 27, Iss. 9, 2004-01 ,pp. : 619-631

Adis International

Access to resources Recommend Favorite

The Cardiovascular Safety Profile of Renzapride, a Novel Treatment for Irritable Bowel Syndrome

By Meyers NL Hickling RI

The Journal of International Medical Research, Vol. 35, Iss. 6, 2007-11 ,pp. : 848-866

Field House Publishing

Access to resources Recommend Favorite